Redeye comments on Fluoguide’s Q1 2023 report as we close in on multiple high-impact catalysts in 2023e. Fluoguide recently updated the market on the timing of readouts and patient recruitment of its ongoing phase II trials. While the new timeline guidance slightly diverged from our previous estimates, we judge that the equity story remains unchanged.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se